CDSCO finds one spurious drug sample in Delhi, 220 NSQs in Aug surveillance
The failed samples during routine regulatory surveillance included 29 tested by the Central Drugs Laboratories
The Central Drugs Standard Control Organisation (CDSCO) discovered a single spurious drug sample and 220 that did not meet quality standards during a random drug surveillance in August, the drugs regulator announced on Tuesday. The failed samples were part of a batch tested by both the Central Drugs Laboratories and State Drugs Testing Laboratories.
NSQ drugs, which do not meet quality standards, can potentially cause serious adverse reactions or death. The spurious drug in Delhi was allegedly manufactured by an unauthorized company using a brand name owned by another company. The matter is currently under investigation, and appropriate action will be taken according to the Drugs and Cosmetics Act and Rules.
CDSCO updates the list of NSQ and spurious drugs monthly on its portal as part of regular regulatory surveillance. The regulator clarified that an NSQ identification is based on failure in one or more quality parameters for a specific drug product and does not affect other products in the market. CDSCO aims to reduce the percentage of less effective drugs, currently around 1.5%, through continuous surveillance in collaboration with State drug regulators.
Written by urgent.news from Hindustan Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
